Fred Wiklund, Bright Peak Therapeutics CEO
Pivoting to ‘ADC-like’ approach, Versant-backed startup gets $90M Series C
Bright Peak Therapeutics announced a $90 million Series C, though its scientific focus and pipeline looks different than it did three years ago.
Shortly after …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.